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Abstract
An etoposide-resistant subline, SBC-3/ETP, from a human small cell lung cancer cell line,
SBC-3, was developed by continuous exposure to increasing concentrations of etoposide in cul-
ture. The SBC-3/ETP was 52.1-fold more resistant to etoposide than the parent cell line. The SBC-
3/ETP was highly cross-resistant to teniposide, adriamycin, vinca alkaloids, 4-hydroperoxycyclophosphamide,
CPT-11 and mitomycin C, and marginally cross-resistant to cisplatin, while the subline showed a
collateral sensitivity to bleomycin. Topoisomerase I activity in the SBC-3/ETP was reduced to an
extent of one half and topoisomerase II activity to an extent of one eighth in comparison with those
of the SBC-3. Intracellular accumulation of [3H]-etoposide in the SBC-3/ETP was significantly
lower in comparison to the SBC-3. An overexpression of MDR1 mRNA, and the presence of its
product, P-glycoprotein, were detected in the SBC-3/ETP by Northern blotting and flowcytometry
using a monoclonal antibody of the protein, MRK16. These results indicate that a decreased ac-
tivity of topoisomerase II is the major factor for the development of etoposide resistance, and that
an overexpression of the MDR1 gene is responsible, in part, for the development of resistance to
the drug and some structurally unrelated compounds such as adriamycin and vinca alkaloids.
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